ORCID Profile
0000-0002-2016-2184
Current Organisation
University of Guilan
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 29-10-2019
DOI: 10.1002/JCP.29346
Abstract: The present study was performed to design an immunotoxin consisting of engineered RNase A and scFv of Cetuximab. To accomplish this study goal, at first to evade RNase A from its inhibitors in the cytoplasm, six amino acids of RNase A were substituted, then the physicochemical features of engineered RNase A were assessed. To investigate the interaction between the engineered RNase A and the ribonuclease inhibitor, protein–protein docking was performed. After engineering the RNase A, it was theoretically conjugated with scFv of Cetuximab using a cleavable linker to produce scFv‐engineered RNase A. Then, wild‐RNase A (14 kD), engineered RNase A (14 kD) and scFv‐engineered RNase A (42 kDa) were expressed in the BL21 (DE3) strain of Escherichia coli and purified by Ni‐NTA columns. To confirm the expressed proteins, western blot analysis was performed. The functioning of wild‐RNase A and engineered RNase A were investigated by RNA fragmentation assay. Finally, to evaluate the cytotoxicity of scFv‐engineered RNase A, a dose–response cytotoxicity assay was performed on Her1‐positive and Her1‐negative cell lines. The results showed that engineered RNase A could maintain its structure and disulfide bonds and evade its inhibitor. Expression and purification were successfully conducted and both enzymes could degrade yeast RNA. The result of cytotoxicity showed that the engineered immunotoxin could induce cell death to Her1‐positive cell lines with an IC 50 of 50 nM. It appears that scFv‐engineered RNase A can be a promising molecule for use.
Publisher: Springer Science and Business Media LLC
Date: 18-08-2018
Publisher: Bentham Science Publishers Ltd.
Date: 22-01-2018
Publisher: Elsevier BV
Date: 08-2009
Publisher: Asian Pacific Organization for Cancer Prevention
Date: 06-11-2014
DOI: 10.7314/APJCP.2014.15.20.8789
Abstract: Estrogen receptor alpha (ERα) is one of the major sub-types of estrogen receptors. ERα plays an important role in cellular proliferation and differentiation, chiefly in mammary tissues. In the present study we aimed to quantify of ERα mRNA and protein expression in breast tissues from the Iranian population using a real-time PCR assay. Twenty nine breast tissues including 19 adenocarcinomas and 10 normal controls were recruited from the Iranian population. mRNA extraction and cDNA synthesis were performed from these tissues using commercial kits. ERα mRNA and protein expression was quantified using real-time PCR and immunohistochemistry respectively. The results showed high expression of ERα mRNA (68%) and protein (53%) in the majority of breast cancer tissues compared to normal breast tissues (p=0.035). Also, high ERα mRNA was associated with tumour size of breast carcinomas. In this study, we first reported the expression of ERα in Iranian patients with breast cancers and demonstrated prevalence of the expression to be similar to breast cancers noted in other populations.
No related grants have been discovered for Shahrokh Ghovvati.